Prostate Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Q4 2010

27 Jan 2011 • by Natalie Aster

“GlobalData analysis finds that the global prostate cancer therapeutics market is attractive and primarily driven by the growth in the hormone-refractory prostate cancer therapeutics market. The growth in the number of total patients receiving treatment and increase in the annual cost of hormone-refractory prostate cancer therapy is expected to offset the impact of generic erosion in hormone-dependent prostate cancer therapy.”

The report “Prostate Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Q4 2010 ” by GlobalData provides comprehensive information on prostate cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the global prostate cancer therapeutics market. It analyses the treatment usage patterns in the global prostate cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. It quantifies the unmet need in the global prostate cancer therapeutics market as well as in the individual markets such as the US and the top five countries in Europe, highlighting the opportunity for future players.

Report Details:

Prostate Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Q4 2010

Published: November 2010
Pages: 436
Price: US$ 15,000.00 US$ 13,500.00
Offer valid until January 31, 2011!

Report Sample Abstract:

The prostate cancer market has relatively high unmet needs in terms of efficacy and safety, with efficacy being the major concern. GlobalData analysis suggests that approximately 38% of the global prostate cancer therapeutics market is underserved. In 2009, the US was the leading market in the global prostate cancer therapeutics market with an estimated market share of approximately 60%. Germany was the second leading market with an approximate market share of 13% followed by France with approximate market share of 7%. The prostate cancer pipeline is strong. Currently, approximately 300 molecules are under development in about 400 research and development projects, including preclinical trials.

More information can be found in the report “Prostate Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Q4 2010 ” by GlobalData.

To order the report or ask for sample pages contact  [email protected]

Contacts

MarketPublishers, Ltd.
Mrs. Alla Martin
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]
www.marketpublishers.com